Selected Toxicities of Targeted Therapies: Presentation and Management

被引：7

作者：

Kollmannsberger, Christian ^{[1
]}

Mitchell, Teresa ^{[1
]}

机构：

[1] British Columbia Canc Agcy, Vancouver Canc Ctr, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada

来源：

SEMINARS IN ONCOLOGY | 2013年 / 40卷 / 04期

关键词：

RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; SUNITINIB; EFFICACY; HYPERTENSION; EVEROLIMUS; TEMSIROLIMUS; BEVACIZUMAB;

D O I：

10.1053/j.seminoncol.2013.05.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：499 / 510

页数：12

共 50 条

[11] Pulmonary toxicities from targeted therapies: a review
Barber, Nicholas A.
Ganti, Apar Kishor
TARGETED ONCOLOGY, 2011, 6 (04) : 235 - 243
[12] Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer
Lacouture, Mario E.
CANCER NURSING, 2007, 30 (04) : S17 - S26
[13] MAPK Pathway - Targeted Therapies Care and management of unique toxicities in patients with advanced melanoma
Rubin, Krista M.
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (06) : 699 - 709
[14] A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
Alasker, Ahmed
Meskawi, Malek
Sun, Maxine
Ismail, Salima
Hanna, Nawar
Hansen, Jens
Tian, Zhe
Bianchi, Marco
Perrotte, Paul
Karakiewicz, Pierre I.
CANCER TREATMENT REVIEWS, 2013, 39 (04) : 388 - 401
[15] Toxicities of new targeted therapies in renal carcinoma.
Cortes, M. N.
Richardet, E.
Richardet, M. E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[16] Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, Grace K.
Adjei, Alex A.
CA-A CANCER JOURNAL FOR CLINICIANS, 2013, 63 (04) : 249 - 279
[17] Toxicities with targeted therapies after immunotherapy in metastatic melanoma
Grogan, Nicole
Swami, Umang
Bossler, Aaron D.
Zakharia, Yousef
Milhem, Mohammed
MELANOMA RESEARCH, 2018, 28 (06) : 600 - 604
[18] Ocular toxicities of MEK inhibitors and other targeted therapies
Stjepanovic, N.
Velazquez-Martin, J. P.
Bedard, P. L.
ANNALS OF ONCOLOGY, 2016, 27 (06) : 998 - 1005
[19] Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management
Belum, Viswanath Reddy
Cercek, Andrea
Sanz-Motilva, Virginia
Lacouture, Mario E.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (03) : 389 - 404
[20] Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management
Viswanath Reddy Belum
Andrea Cercek
Virginia Sanz-Motilva
Mario E. Lacouture
Current Treatment Options in Oncology, 2013, 14 : 389 - 404

← 1 2 3 4 5 →